Antiseizure medications and their differing effects on cardiovascular risk
This review discusses the differing effects of enzyme-inducing and non-inducing antiseizure medications on cardiovascular risk and their implications for the management strategies of epilepsy patients. Traditional risk markers, including low density lipoprotein, high density lipoprotein and triglyce...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Epilepsy & Behavior Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589986425000061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864278481895424 |
|---|---|
| author | Aleena Abbasi Bassil Abbasi Scott Mintzer Carla LoPinto-Khoury |
| author_facet | Aleena Abbasi Bassil Abbasi Scott Mintzer Carla LoPinto-Khoury |
| author_sort | Aleena Abbasi |
| collection | DOAJ |
| description | This review discusses the differing effects of enzyme-inducing and non-inducing antiseizure medications on cardiovascular risk and their implications for the management strategies of epilepsy patients. Traditional risk markers, including low density lipoprotein, high density lipoprotein and triglycerides, can be altered by both enzyme induction and inhibition. Other markers of vascular risk, including c-reactive protein, non-high-density lipoprotein and homocysteine, are affected by antiseizure medications, although adults and children may have different responses. The overall atherosclerotic risk picture is more complex due to indirect effects such as neuroendocrine function and the metabolic syndrome. Large scale data shows an evolving understanding of cardiovascular risk. Long term risks of enzyme inducing antiseizure medications and valproic acid are apparent when studies examine medications individually. Finally, effects of antiseizure medications on cardiac rhythm and possibly autonomic control are discussed with respect to their clinical relevance to the practicing clinician. |
| format | Article |
| id | doaj-art-d546f0fcdde04fd1ba10759bd42f16cb |
| institution | Kabale University |
| issn | 2589-9864 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Epilepsy & Behavior Reports |
| spelling | doaj-art-d546f0fcdde04fd1ba10759bd42f16cb2025-02-09T05:01:01ZengElsevierEpilepsy & Behavior Reports2589-98642025-03-0129100746Antiseizure medications and their differing effects on cardiovascular riskAleena Abbasi0Bassil Abbasi1Scott Mintzer2Carla LoPinto-Khoury3Department of Neurology, Temple University, Philadelphia, PA, United States; Corresponding author.Department of Neurology, Temple University, Philadelphia, PA, United StatesDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Neurology, Temple University, Philadelphia, PA, United StatesThis review discusses the differing effects of enzyme-inducing and non-inducing antiseizure medications on cardiovascular risk and their implications for the management strategies of epilepsy patients. Traditional risk markers, including low density lipoprotein, high density lipoprotein and triglycerides, can be altered by both enzyme induction and inhibition. Other markers of vascular risk, including c-reactive protein, non-high-density lipoprotein and homocysteine, are affected by antiseizure medications, although adults and children may have different responses. The overall atherosclerotic risk picture is more complex due to indirect effects such as neuroendocrine function and the metabolic syndrome. Large scale data shows an evolving understanding of cardiovascular risk. Long term risks of enzyme inducing antiseizure medications and valproic acid are apparent when studies examine medications individually. Finally, effects of antiseizure medications on cardiac rhythm and possibly autonomic control are discussed with respect to their clinical relevance to the practicing clinician.http://www.sciencedirect.com/science/article/pii/S2589986425000061Antiseizure medications (ASMs)Cardiovascular riskEpilepsy managementenzyme-inducing ASMs (EIASMs)non-enzyme-inducing ASMs (NEIASMs)Lipid profile |
| spellingShingle | Aleena Abbasi Bassil Abbasi Scott Mintzer Carla LoPinto-Khoury Antiseizure medications and their differing effects on cardiovascular risk Epilepsy & Behavior Reports Antiseizure medications (ASMs) Cardiovascular risk Epilepsy management enzyme-inducing ASMs (EIASMs) non-enzyme-inducing ASMs (NEIASMs) Lipid profile |
| title | Antiseizure medications and their differing effects on cardiovascular risk |
| title_full | Antiseizure medications and their differing effects on cardiovascular risk |
| title_fullStr | Antiseizure medications and their differing effects on cardiovascular risk |
| title_full_unstemmed | Antiseizure medications and their differing effects on cardiovascular risk |
| title_short | Antiseizure medications and their differing effects on cardiovascular risk |
| title_sort | antiseizure medications and their differing effects on cardiovascular risk |
| topic | Antiseizure medications (ASMs) Cardiovascular risk Epilepsy management enzyme-inducing ASMs (EIASMs) non-enzyme-inducing ASMs (NEIASMs) Lipid profile |
| url | http://www.sciencedirect.com/science/article/pii/S2589986425000061 |
| work_keys_str_mv | AT aleenaabbasi antiseizuremedicationsandtheirdifferingeffectsoncardiovascularrisk AT bassilabbasi antiseizuremedicationsandtheirdifferingeffectsoncardiovascularrisk AT scottmintzer antiseizuremedicationsandtheirdifferingeffectsoncardiovascularrisk AT carlalopintokhoury antiseizuremedicationsandtheirdifferingeffectsoncardiovascularrisk |